editor
journal
freeman
colleagu
describ
evalu
nation
microbiolog
surveil
system
autom
outbreak
detect
england
chines
govern
also
establish
similar
surveil
system
outbreak
sever
acut
respiratori
syndrom
system
compris
webbas
diseas
report
system
nation
infecti
diseas
monitor
inform
system
databas
resourc
help
strengthen
chines
infecti
diseas
prevent
control
strategi
exampl
outbreak
influenza
influenza
swiftli
detect
effect
control
moreov
outbreak
import
wildtyp
polioviru
quickli
detect
system
vulner
popul
vaccin
led
success
termin
outbreak
within
month
laboratori
confirm
index
case
addit
china
populationbas
vaccin
program
nation
microbiolog
surveil
system
substanti
contribut
control
infecti
diseas
china
last
year
fig
accord
chines
government
report
sever
acut
respiratori
syndrom
erad
last
year
four
case
plagu
case
diphtheria
filariasi
sinc
decreas
report
number
case
anthrax
cholera
leptospirosi
epidem
cerebrospin
mening
neonat
tetanu
typhu
fever
epidem
hemorrhag
fever
typhoid
paratyphoid
fever
untyp
viral
hepat
hepat
gonorrhea
bacteri
ameb
dysenteri
furthermor
although
number
report
case
kalaazar
rabi
epidem
enceph
b
malaria
rubella
report
number
infecti
diseas
increas
china
compar
previous
observ
fig
believ
attribut
microb
abl
spread
easili
owe
dirti
environ
chang
climat
popul
migrat
nation
microbiolog
surveil
system
abl
effect
promptli
detect
chang
statu
although
china
effect
reduc
number
pertussi
case
number
case
significantli
higher
although
fewer
measl
case
report
vs
incid
higher
incid
number
report
hepat
e
case
also
increas
sinc
similarli
number
report
acut
hemorrhag
conjunct
influenza
case
higher
respect
compar
number
exclud
outbreak
respect
furthermor
number
report
syphili
brucellosi
scarlet
fever
schistosomiasi
echinococcosi
hepat
c
case
exhibit
fluctuat
sharpli
increas
trend
approxim
case
report
conclus
china
england
effect
implement
nation
microbiolog
surveil
system
adopt
similar
system
countri
especi
africa
countri
may
enabl
public
health
author
quickli
collect
inform
make
effect
decis
combat
potenti
ongo
outbreak
figur
number
report
infecti
diseas
case
china
leprosi
kalaazar
anthrax
cholera
leptospirosi
epidem
cerebrospin
mening
b
neonat
tetanu
rabi
echinococcosi
typhu
fever
pertussi
schistosomiasi
c
epidem
enceph
b
epidem
hemorrhag
fever
hepat
e
aid
dengu
fever
typhoid
paratyphoid
fever
brucellosi
malaria
scarlet
fever
untyp
viral
hepat
hepat
acut
hemorrhag
conjunct
e
rubella
hepat
c
gonorrhea
measl
influenza
syphili
f
mump
bacteri
ameb
dysenteri
infecti
diarrhea
hepat
b
pulmonari
tuberculosi
handfootandmouth
diseas
untyp
viral
hepat
viral
hepat
case
except
case
hepat
b
c
e
infecti
diarrhea
case
infecti
diarrhea
list
prophylaxi
pneumocysti
jirovecii
pneumonia
patient
adult
tcell
lymphomaleukemia
receiv
anticc
chemokin
receptor
monoclon
antibodi
recent
kim
colleagu
journal
report
characterist
pneumocysti
jirovecii
pneumonia
pjp
patient
without
hiv
infect
although
pjp
remain
caus
nonrelaps
morbid
mortal
patient
without
hiv
infect
includ
adult
tcell
leukemialymphoma
atll
observ
trimethoprimsulfamethoxazol
tmpsmx
effect
prophylact
atll
patient
receiv
chemotherapeut
agent
immunosuppress
includ
novel
antibodi
mogamulizumab
human
anticc
chemokin
receptor
monoclon
antibodi
clinic
antitumor
effect
patient
relaps
atll
mogamulizumab
avail
clinic
practic
sinc
may
japan
although
combin
mogamulizumab
vincristin
cyclophosphamid
doxorubicin
prednison
ranimustin
vindesin
etoposid
carboplatin
vcapampvecp
chemotherapi
show
better
complet
respons
rate
phase
ii
clinic
trial
pjp
report
aim
highlight
prophylact
effect
pjp
mogamulizumab
therapi
postchemotherapi
crucial
success
vcapampvecp
chemotherapi
mogamulizumab
upfront
treatment
regimen
atll
nineti
atll
patient
acut
n
z
lymphoma
n
z
type
atll
receiv
chemotherapi
includ
cyclophosphamid
doxorubicin
vincristin
prednison
chop
n
z
chop
plu
etoposid
mitoxantron
ranimustin
vindesin
chopvmmv
n
z
vcapampvecp
n
z
chop
plu
etoposid
chope
n
z
modifi
etoposid
prednison
vincristin
cyclophosphamid
doxorubicin
epoch
n
z
mogamulizumab
n
z
may
institut
retrospect
evalu
tabl
median
four
patient
rang
treat
mogamulizumab
mgkgweek
patient
receiv
trimethoprimsulfamethoxazol
prophylaxi
n
z
treatment
n
z
pjp
although
patient
pjp
diagnosi
atll
die
respiratori
failur
case
pjp
chemotherapi
alon
combin
mogamulizumab
twentythre
patient
receiv
allogen
hematopoiet
cell
transplant
hct
three
patient
receiv
chemotherapi
mogamulizumab
allogen
hct
die
graftversushost
diseas
gvhd
outbreak
pjp
ten
patient
patient
receiv
chop
mogamulizumab
patient
receiv
chemotherapi
alon
requir
reduct
dose
schedul
trimethoprimsulfamethoxazol
tmpsmx
advers
drug
reaction
adr
rash
n
z
thrombocytopenia
n
z
eleven
patient
chemotherapi
combin
mogamulizumab
patient
chemotherapi
alon
success
complet
oral
mg
tmp
plu
mg
smx
daili
mg
tmp
plu
mg
smx
twice
week
tabl
patient
stop
tmpsmt
prophylaxi
adr
prophylaxi
pjp
atll
patient
consid
particularli
patient
elig
allogen
hct
occurr
gvhd
impair
immun
reconstitut
requir
prolong
intens
immunosuppress
therapi
allogen
hct
howev
gvhd
still
high
risk
pjp
prophylaxi
pjp
atll
patient
receiv
chemotherapi
highli
recommend
nationwid
survey
japan
observ
tmpsmx
firstlin
prophylact
agent
prevent
pjp
atll
patient
summari
evid
nationwid
survey
support
retrospect
cohort
studi
tmpsmx
prophylaxi
use
case
pjp
chemotherapi
alon
combin
mogamulizumab
observ
limit
studi
includ
retrospect
natur
involv
singl
institut
evalu
warrant
estim
incid
pjp
establish
best
time
start
stop
prophylaxi
pjp
atll
patient
candid
treatment
mogamulizumab
particularli
elig
allogen
hct
